Tiziana Life Sciences (TLSA) said Thursday that it will advance its second asset, TZLS-501, a monoclonal antibody targeting inflammation, lung damage, and chronic fibrosis in multiple diseases, including rheumatoid arthritis, acute respiratory distress syndrome, lupus, and various cancers.

Tiziana said it will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.

The company said it sees the potential to develop TZLS-501 as either a monotherapy or in combination with foralumab as well as with other anti-inflammatory and anti-infective agents.

Tiziana said its pursuit of the development of TZLS-501 will not divert resources or focus from ongoing clinical trials with foralumab.

Shares of Tiziana were down 1% in recent premarket activity Thursday.